The week in pharma: action, reaction and insight – week to March 25, 2022

27 March 2022

By Barbara Obstoj-Cardwell. Editor

Clinical trial news last week included ADC specialist ImmunoGen releasing data from the SORAYA trial of its mirvetuximab soravtansine (Mirasol) that did not impress investors. On the regulatory front, Bristol Myers Squibb gained US Food and Drug Administration approval for a new metastatic melanoma treatment Opdualag, a combination of nivolumab and relatlimab. Also, MEI Pharma and Kyowa Kirin’s hopes of an early approval from the FDA for their P13K inhibitor zandelisib suffered a set back last Thursday. Meantime, at its vaccines day presentation, Moderna upped expectations for its COVID-19 vaccines.

ImmunoGen’s mirvetuxumab trial goes down to the wire

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK